Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-NKG2DLs CAR-T cells LEU011

A preparation of autologous T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting natural-killer group 2, member D ligands (NKG2DLs), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-NKG2DLs CAR-T cells LEU011 specifically recognize and induce selective toxicity in tumor cells expressing NKG2DLs. Ligands for NKG2D, such as MHC class I chain-related protein A (MICA), MICB, and members of the UL16-binding proteins (ULBP)/retinoic acid early transcript 1 (RAET1) family, are overexpressed on various cancer cell types, but are not expressed on most normal, healthy cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous anti-NKG2DL CAR T cells LEU 011
autologous NKG2D ligands-targeting CAR T cells LEU011
autologous NKG2DLs-targeting CAR T cells LEU011
Code name:LEU 011
LEU-011
LEU011
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search